Evidence map›Paper›PMID 23070347›Full record

Trial reportClinics (Sao Paulo, Brazil)2012

Pharmacokinetics of cyclosporin--a microemulsion in children with idiopathic nephrotic syndrome.

Luciana dos Santos Henriques, Fabíola de Marcos Matos, Maria Helena Vaisbich

Registry-linked trialOpen access · goldAbstract readClinical Trial
In one paragraph

Trial report in Clinics (Sao Paulo, Brazil), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01616446 (PHARMACOKINETICS OF CYCLOSPORIN - A MICROEMULSION IN CHILDREN WITH IDIOPATHIC NEPHROTIC SYNDROME), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01616446 completednot on this map

Pharmacokinetics of cyclosporin - a microemulsion in children with idiopathic nephrotic syndrome

TypeobservationalSponsorUniversity of Sao PauloRan2007 to 2010Enrolled10ConditionsNephrotic Syndrome
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Cyclosporine A CClinical and experimental nephrology · 2022
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Luciana dos Santos HenriquesInstituto da Criança, Faculdade de Medicina, Universidade de São Paulo, São Paulo/SP, Brazil. lushenriques@gmail.com
Fabíola de Marcos Matos
Maria Helena Vaisbich
Universidade de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveWe present a prospective study of a microemulsion of cyclosporin to treat idiopathic nephrotic syndrome in ten children with normal renal function who presented cyclosporin trough levels between 50 and 150 ng/ml and achieved complete remission with cyclosporin. To compare the pharmacokinetic parameters of cyclosporin in idiopathic nephrotic syndrome during remission and relapse of the nephrotic state.

methodThe pharmacokinetic profile of cyclosporin was evaluated with the 12-hour area under the time-concentration curve (auc0-12) using seven time-point samples. This procedure was performed on each patient during remission and relapse with the same cyclosporin dose in mg/kg/day. The 12-hour area under the time-concentration curve was calculated using the trapezoidal rule. All of the pharmacokinetic parameters and the resumed 4-hour area under the time-concentration curve were correlated with the 12-hour area under the time-concentration curve. ClinicalTrials.gov: NCT01616446.

resultsThere were no significant differences in any parameters of the pharmacokinetic of cyclosporin during remission and relapse, even when the data were normalized by dose. The best correlation with the 12-hour area under the time-concentration curve was the 4-hour area under the time-concentration curve on remission and relapse of the disease, followed by the 2-hour level after cyclosporin (c2) dosing in both disease states.

conclusionsThese data indicate that the same parameters used for cyclosporin therapeutic monitoring estimated during the nephrotic state can also be used during remission. Larger controlled studies are needed to confirm these findings.

Indexed as

AdolescentArea Under CurveChildChild, PreschoolCholesterolCreatinineCyclosporineFemaleHumansImmunosuppressive AgentsMaleNephrotic SyndromeProspective StudiesProteinuriaSerum AlbuminTime FactorsCholesterolCreatinineCyclosporineImmunosuppressive AgentsSerum Albumin

Identifiers

PMID23070347
PMCPMC3460023
OpenAlexW2024314930

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.